tbuckley/cabot-search huggingface dataset:
Prognostic Analysis of GATA2 Mutations in CEBPA-Mutated Acute Myeloid Leukemia
Authors: Alice Marceau-Renaut, Meyling Cheok, Nicolas Duployez, Olivier Nibourel, Nathalie Helevaut, Céline Rodriguez, Karine Celli-Lebras, Céline Berthon, Guy Leverger, Nicolas Boissel, Christine Terré, Xavier Thomas, Sylvie Castaigne, Herve Dombret, Claude Preudhomme, Aline Renneville
Journal: Blood (2014)
Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2
Authors: Ashok V Purandare, Animesh Pardanani, Theresa McDevitt, Marco Gottardis, Terra Lasho, Dan You, Louis Lombardo, Becky Penhallow, Ragini Vuppugalla, George Trainor, Ayalew Tefferi, Matthew Lorenzi
Journal: Blood (2010)
Concordance of PET/CT and bone marrow biopsy in lymphoma staging
Authors: F. Crepaldi, F. Broggio, B. Bocci, C. Careri, N. Battisti, M. Violati, V. Bordin, S. Caldiera, C. Codecà, A. Luciani, S. Zonato, G. Cassinelli, P. Foa, D. Ferrari
Journal: Annals of Oncology (2015)
Relationship between Psychophysical Measures of Retinal Ganglion Cell Density and In Vivo Measures of Cone Density in Glaucoma
Authors: Juliane Matlach, Pádraig J. Mulholland, Marketa Cilkova, Reena Chopra, Nilpa Shah, Tony Redmond, Steven C. Dakin, David F. Garway-Heath, Roger S. Anderson
Journal: Ophthalmology (2016)
Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma
Authors: Peter Martin, Kami J. Maddocks, Katherine Noto, Beth Christian, Richard R. Furman, Leslie A. Andritsos, Joseph M Flynn, Jeffrey A. Jones, Jia Ruan, Selina Chen-Kiang, Maurizio Di Liberto, John P. Leonard, Kristie A. Blum
Journal: Blood (2014)
PTU-038 Medical Malpractice in Endoscopy: What are We Getting Wrong?
Authors: S Budihal, JF Mayberry
Journal: Gut (2016)

<h3>Introduction</h3> Adverse clinical events can lead to patients seeking compensation citing medical negligence. Endoscopy is not risk free and complications are well documented. Information regarding claims in endoscopy is scarce and little is known about the causes for legal redress. This study aimed to investigate the nature of medico-legal claims in relation to endoscopy in the National Health Service. <h3>Methods</h3> The National Health Service Litigation Authority’s(NHSLA) database was searched for Endoscopy claims between the year of 2010/11 to 2014/2015 using the terms "Endoscopy", "Gastroscopy", "Colonoscopy", "Sigmoidoscopy", "ERCP" and "Capsule Endoscopy" through a Freedom of Information Request (F/2405). Causes for the claims and nature of the procedures were then analysed. <h3>Results</h3> A total of 151,23, 118, 35, 43 and 72 claims were recorded with the terms Endoscopy, Gastroscopy, Colonoscopy, Sigmoidoscopy, PEG and ERCP in the incident descriptions. Only one case involving Capsule Endoscopy was noted. Claims relating to Infection control and Hospital hygiene topped the list, followed by a failure or delay in diagnosing a condition. Claims also centred on incidents during endoscopy, along with a failure to adequately take an informed consent. Inadequate nursing care was a significant factor in claims relating to PEG procedures. <h3>Conclusion</h3> This study shows that the majority of claims pertain to Colonoscopy or ERCP. Infection Control and Failure to diagnose and treat conditions are important causes for litigation.Capsule Endoscopy appears to be relatively risk free.Endoscopist should bear these factors in mind when obtaining consent and undertaking procedures.Further studies are required for a more detailed analysis of litigation in endoscopy to ensure safer medical practice and patient care. <h3>Disclosure of Interest</h3> None Declared
High Circulating Vascular Endothelial Growth Factor Receptor-1 Correlates with Increased Microvessel Density and Inferior Survival in Newly-Diagnosed Patients with Multiple Myeloma Who Receive Frontline Therapy with Novel Agent-Based Regimens
Authors: Gerasimos-Petros Papassotiriou, Evangelos Terpos, Efstathios Kastritis, Maria Gkotzamanidou, Filia Apostolakou, Evangelos Eleutherakis-Papaiakovou, Meletios Athanasios Dimopoulos
Journal: Blood (2011)
PRIMARY EXTRANODAL MARGINAL ZONE LYMPHOMA of the LUNG (BALT-LYMPHOMA): Results of a Retrospective Analysis on Behalf of IELSG
Authors: Simona Sammassimo, Giancarlo Pruneri, Stefano A. Pileri, Paola Rafaniello, Sara Steffanoni, Sara Gandini, Mara Negri, Pier Luigi Zinzani, Markus Raderer, Patrick Adam, James O. Armitage, Dennis D. Weisenburger, Osnat Bairey, Maria Cabrera, Emanuele Zucca, Luigi Rigacci, Gonzalo Gutierrez-Garcia, Andrea Carpaneto, Caroline Besson, Ewa Kalinka Warzocha, Franco Cavalli, Giovanni Martinelli
Journal: Blood (2010)
PWE-008 Factors Associated with Voluntary Childlessness in Women with IBD
Authors: C Selinger, J Ghorayeb, A Madill
Journal: Gut (2016)

<h3>Introduction</h3> Inflammatory Bowel Disease (IBD) affects many women of child bearing age, but requires complex decision making around pregnancy. While infertility is only slightly increased many women decide against having children. Voluntary childlessness (VC) rates exceed those of the general population by far. The reasons for VC remain incompletely understood. <h3>Methods</h3> Approximately 4300 female members of the patient organisation Crohn’s and Colitis UK aged 18–45 years were asked by email to complete an online questionnaire. Data collection included patient demographics, education, employment, marital status, and disease characteristics. Childlessness status and patient views were assessed as in the previous study by Marri (2007). Disease related pregnancy knowledge was recorded with the validated CCPKnow score. <h3>Results</h3> 1324 women with mean age of 33 years completed the survey (response rate 31%). Of these 76% were in a long-term relationship and 87% were in employment or education. 776 (59%) suffered from Crohn’s disease (CD), 496 (38%) from ulcerative colitis (UC) and 4% from IBD-U. 40% had children [14% pre diagnosis (I); 26% post diagnosis (II)], 36% planned to have children at some stage (III), 7% reported fertility problems (IV) and 17% were classified as voluntarily childless (VC). 673 patients had sought medical advice about pregnancy and IBD. VC was associated with poorer disease-related knowledge (CCPKnow 5.98 vs 7.47 in (II); p &lt; 0.001), older age (35 y vs 28 y in (II); p &lt; 0.001), unemployment (9.7% VC; p &lt; 0.001), being single (34.5% VC; p &lt; 0.001, not seeking medical advice (p &lt; 0.001), and diagnosis of CD (19.3% vs 13.9% UC; p = 0.015). Women with VC had more hospital admissions (mean 2.85 vs 2.17 (III); p = 0.03) and surgical interventions (mean 1.27 vs 0.65 (III); p &lt; 0.001). Exposure with different types of IBD medication was not associated with VC. The main patient concerns were around inheritance (20.6%), inability to cope with a child (20.6%), and the influence of pregnancy on IBD (18%). <h3>Conclusion</h3> VC occurs frequently in women with IBD and appears to be multifactorial. Disease type and severity influence VC. Differences in disease burden could explain why VC is more common in CD than UC. Patients are mostly concerned regarding inheritability, disease course and the ability to cope with the added stress of being a mother.VC is associated with poor pregnancy specific knowledge and many women may stay childless unnecessarily. Patient education programs may help to reduce the rate of VC by correcting misconceptions and alleviating patient concerns. <h3>Disclosure of Interest</h3> C. Selinger Grant/research support from: Abbvie, Warner Chilcott, Consultant for: Abbvie, Warner Chilcott, Dr Falk, Takeda, Speaker bureau with: Abbvie, Warner Chilcott, MSD, Takeda, J. Ghorayeb: None Declared, A. Madill: None Declared
Development of New Autoimmunity Against T Cell Antigens Derived From Retinal Proteins After Allogeneic Hematopoietic Cell Transplantation.
Authors: Nora Roth, Christoph Faul, Christiane Dorn, Wichard Vogel, Wolfgang A. Bethge, Lothar Kanz, Hans-Georg Rammensee, Sebastian P. Haen
Journal: Blood (2012)
Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)
Authors: Andreas Hochhaus, Timothy P. Hughes, Giuseppe Saglio, François Guilhot, Haifa Kathrin Al-Ali, Giantonio Rosti, Chiaki Nakaseko, Carmino Antonio De Souza, Charisse Kemp, Xiaolin Fan, Albert Hoenekopp, Richard A. Larson, Hagop M. Kantarjian
Journal: Blood (2012)
Significantly Reduce Acute Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation by Using Cord Blood as the Third Party Cells.
Authors: Dao-Pei Lu, Tong Wu, Zhi-Yong Gao, Jing-Bo Wang, Xing-Yu Cao, Yan-Li Zhao, Lujia Dong, Yu-Ming Yin, Shu-Quan Ji, Wan-Ming Da
Journal: Blood (2008)
PTU-124 The Treatment Needs of Patients with Gastrointestinal Disorders in Tertiary Functional Versus Pooled Psychology Clinics
Authors: G Fairclough, J Ablett, P Paine
Journal: Gut (2016)

<h3>Introduction</h3> Psychological and physical co-morbidity is associated with poorer outcomes and higher service use for patients with gastrointestinal (GI) disorders. This study aimed to evaluate the treatment needs of patients with GI disorders in tertiary functional versus pooled GI psychology clinics. <h3>Methods</h3> 67 patients (49 females; mean age 42; range 17–86) completed questionnaires on accessing a tertiary functional (n = 36) and pooled (all causes) GI psychology clinic (n = 31). The Gastrointestinal Symptom Rating Scale (GSRS), Work and Social Adjustment Scale (WSAS), Patient Health Questionnaire (PHQ-9), Generalised Anxiety Disorder Questionnaire (GAD-7) and Visceral Sensitivity Index (VSI) were completed. Mann-Whitney U-test was used for comparison of samples. <h3>Results</h3> Severity across measures was high amongst both samples. 31% of tertiary functional patients (n = 35) and 37% of pooled GI psychology (n = 30) patients scored within the ‘severe range’ for all three areas of need; GI symptom severity, functional impairment and distress. 67% of patients within the tertiary clinic were above cut off for clinically significant distress compared with 90% in the pooled GI psychology clinic. No significant differences were found between the two groups of patients for GI symptom severity (U = 527, <i>p</i><i> =</i>0.697), functional impairment (U = 532, <i>p</i><i> =</i>0.951), GI-specific distress (U = 502.5, <i>p</i><i> =</i>0.949) or depression (U = 403, <i>p</i><i> =</i>0.078). Patients seen within the GI Psychology clinic scored significantly higher for generalised anxiety (U = 350, <i>p</i><i> =</i>0.014). <h3>Conclusion</h3> Clinically significant high levels of GI symptom severity, functional impairment and psychological distress were reported across the samples. This was expected as referral indication to the pooled GI psychology clinic, but surprisingly high in the tertiary functional clinic. This supports developing integrated psychological services within this GI sub–speciality to provide interventions for health-related distress. Generalised anxiety was significantly higher within the pooled psychology sample. Future studies may determine whether GI patients with less overt anxiety, but nonetheless significant psychological needs, are at risk of under-referral to psychology. Use of questionnaires may identify psychological co-morbidity within gastroenterology services to triage appropriate and timely referrals for psychological therapy. <h3>Disclosure of Interest</h3> None Declared
PWE-141 Impact of The ‘Be Clear On Cancer’ National Oesophago-Gastric Cancer Awareness Campaign on Endoscopy Services and Cancer Diagnosis Rates and Outcomes
Authors: M Kabir, D Khoo
Journal: Gut (2016)

<h3>Introduction</h3> Previous regional pilot studies have suggested that media campaigns for upper gastrointestinal (UGI) cancers successfully increase public awareness of symptoms, increase two-week wait pathway (2 WW) general practitioner (GP) referrals and increase the numbers of cancers diagnosed.<sup>1</sup> This prompted the roll-out of a nationwide televised media campaign, which promoted dyspepsia as a sign of cancer, from 26 th January to 22 nd February 2015. This study aimed to evaluate its impact, which is not well known to date, on the numbers of GP referrals made to a high volume endoscopy unit in London and the numbers and prognosis of the cancers diagnosed. <h3>Methods</h3> This was a retrospective observational study, analysing departmental and patient records at the Barking, Havering and Redbridge Hospitals NHS Trust. Total numbers of GP 'urgent' priority and 'two-week wait' (2 WW) cancer pathway referrals for UGI endoscopies were collected from a six month period before the onset of the campaign and compared with a six month period after the campaign onset. The total numbers, demographics and outcomes of the oesophago-gastric cancers referred and diagnosed in the pre- and post-campaign period were recorded. Student paired t tests and χ2 tests were used to assess for statistical significance. <h3>Results</h3> There were 1143 urgent/2 WW UGI endoscopy referrals made by GP's in the pre-campaign period and 1448 referrals in the post-campaign period. There was a statistically significant rise of mean monthly 2 WW referrals in the post-campaign period by 36.5% (p = 0.001). The extra demand was most noticeable in the 2 month post-campaign period with a mean weekly referral rate increase of 46.5% (p = 0.001), equating to 20 extra UGI endoscopies requested per week. However, there was no statistically significant change in the overall rates of oesophago-gastric cancers detected in any age group (47 cancers pre-campaign vs. 38 post-campaign), in their staging or the proportion that could be treated with curative intent. Most of the cancers diagnosed in both groups actually presented as dysphagia (35–37%) and/or weight loss (22–27%) rather than dyspepsia (10–11%). <h3>Conclusion</h3> The national oesophago-gastric cancer awareness campaign significantly increased the demand placed on endoscopy services but did not meet its aim of detecting more cancers at an earlier curative stage. Most diagnosed were still in advanced stages 3 and 4. Perhaps future campaigns should place more emphasis on promoting awareness of dysphagia, which was more strongly associated with cancer detection, in addition to dyspepsia, in order to increase cancer detection rates. <h3>Reference</h3> 1 Cancer Research UK literature: http://naedi.org/beclearoncancer/oesophago-gastric <h3>Disclosure of Interest</h3> None Declared
A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP).
Authors: Hagop M. Kantarjian, Norbert Gattermann, Andreas Hochhaus, Richard Larson, Teresa Rafferty, Aaron Weitzman, Ariful Haque, Francis Giles, S.G. O’Brien, Philipp le Coutre
Journal: Blood (2006)
What is running economy? A clinician's guide to key concepts, applications and myths
Authors: James M Smoliga
Journal: British Journal of Sports Medicine (2016)

Running economy is one of the key physiological predictors of distance running performance1 and articles about running economy are abundant in the scientific and lay communities. Clinicians regularly encounter coaches and athletes aiming to improve performance and may also recommend injury-related interventions which influence running economy, and therefore should have a firm understanding of running economy. However, running economy is often misunderstood and measured in an inconsistent or unjustified manner. As such, it can be difficult to make sense of the literature regarding how demographics, biomechanics (eg, stride rate, footstrike) and interventions (eg, footwear, orthoses, biomechanical alterations, training programmes) influence running economy, thus performance. Here, I address five critical questions about running economy so that existing research can be interpreted appropriately and clinicians can accurately advise athletes. Additionally, the online supplementary appendix provides further relevant concepts and examples to demonstrate these points.

### Supplementary appendix

[bjsports-2016-096159supp_Appendix.pdf]

Running economy is defined as the aerobic demands of running, or the relationship between oxygen consumption (VO2: expressed in units of L O2/min or mL O2/kg/min) and running speed.2 In trained runners with similar maximal aerobic capacity (VO2max), those with superior running economy (lower VO2 per unit distance: mL O2/kg/km) achieve faster racing times2 due to reduced metabolic demand at submaximal intensities. Likewise, excellent running economy may compensate for VO2max limitations, even at the elite level1 where athletes may have reached their individual physiological boundaries.

Running economy is typically measured using a motorised treadmill, using a protocol that allows individuals to run at progressively faster speeds, while steady-state VO2 is measured using a metabolic cart. Running economy may also be measured on a running track …
FRI0252 Efficacy of Mycophenolate Mofetil (MMF) versus Oral Cyclophosphamide (CYC) on Skin Thickness in The Scleroderma Lung Study II: Table 1.
Authors: D. Khanna, D. Tashkin, D.E. Furst, C.-H. Tseng, H. Wilhalme, M. Roth, S. Kafaja, E. Volkmann, R. Elashoff, P. Clements
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Mycophenolate mofetil (MMF) has been shown to improve skin thickness, as assessed by the modified Rodnan skin score (mRSS), in patients with diffuse cutaneous SSc (dcSSc) in retrospective analyses of different cohorts (1). In addition, oral cyclophosphamide (CYC) had a favorable impact on mRSS in SLS-I (2). <h3>Objectives</h3> Our objectives were to: 1. Assess the impact of MMF and CYC on the mRSS in a randomized controlled trial of MMF vs. oral CYC in patients with symptomatic scleroderma-related interstitial lung disease (SLS II) over 24 months, and 2. Compare the improvement in mRSS in the SLS I vs. SLS II cohorts at 6 and 12 months. <h3>Methods</h3> 142 patients with SSc-ILD were randomized in the SLS II. Patients received MMF (≤3 g daily) for two years or oral CYC (≤2 mg per kilogram of body weight) for one year followed by placebo twice daily for an additional year. In addition, we compared the change in mRSS in the dcSSc subset in the SLS-II vs. SLS-I oral CYC (≤2 mg per kilogram of body weight) and matching placebo prescribed for 1 year. <h3>Results</h3> The baseline (mean± SD) disease duration was 2.6±1.8 years and mRSS was 14.0±10.6 for CYC and 15.3±10.4 for MMF groups in the SLS II; 58.5% were classified as dcSSc and 42.5% were classified as limited cutaneous SSc (lcSSc). Both treatments were associated with improvement in mRSS over the period of 24 months but there was no statistically significant between 2 groups at any time points in the dcSSc and lcSSc subsets (p&gt;0.05 for all comparisons). The mean improvement in the CYC group was 1.4 vs. 2.0 in the MMF group in the lcSSc subset and 8.0 vs. 6.3 in the dcSSc subset at 24 months. For our second objective, there was no statistical difference in the baseline mRSS scores in the dcSSc in SLS-I (mean disease duration=3.1 years) and SLS-II (mean disease duration=2.5 years) trials (Table). In addition, the change in mRSS at 6- and 12-month period was similar in the SLS-II pooled (MMF+ CYC) and SLS-I CYC groups (Table; p&gt;0.05). In contrast, SLS-II pooled and SLS-I CYC groups showed statistically significant improvement at 12-month period vs. SLS-1 placebo group (p&lt;0.05). <h3>Conclusions</h3> In the SLS II, 2 years of daily MMF and 1-year of CYC were associated with clinically important improvements in mRSS in the dcSSc over 24 months. The change in mRSS in the SLS-II paralleled that in the SLS-I CYC group and was significantly superior to the SLS-I placebo group. These data support the use of MMF or CYC for management of skin fibrosis in early dcSSc. <h3>References</h3> Le et al Ann Rheum Dis 2011 Tashkin et al NEJM 2006 <h3>Acknowledgement</h3> SLS I and SLS II were funded by NIH/NHLBI <h3>Disclosure of Interest</h3> None declared
Phase II Prospective Multicenter Study of Treosulfan Based Reduced Intensity Conditioning In Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies From 10/10 HLA Identical Unrelated Donor
Authors: Mauricette Michallet, Mohamad Sobh, Stephane Morisset, Nathalie Tedone, Jacques-Olivier Bay, Jean-Luc Harousseau, Mohamad Mohty, Ibrahim Yakoub-Agha, Agnes Buzyn, Noel Milpied, Franck E Nicolini, Helene Labussiere, Joachim Baumgart, Nicole Raus, Reza Tabrizi, Didier Blaise
Journal: Blood (2010)
SAT0074 Patients with knee osteoarthritis treated by hylan g-f 20 versus usual treatments: a medico-economic, prospective, randomised large scale trial in france, medico-economic outcomes
Authors: A Kahan, E Guemas, PL Lleu
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To evaluate the medico-economic benefits of Hylan G-F 20 over 9 months in the treatment of patients suffering from knee osteoarthritis (OA). <h3>Methods</h3> Patients with radiographically proven knee OA, pain on movement ³ 40 mm (VAS) and treated by at least two 10-day NSAIDs courses or by slow-acting anti-OA drugs within the previous 3 or 2 months respectively were enrolled by 81 centres (21 hospitals and 60 private rheumatologists). After stratification on known OA risk factors (patients? age, BMI,...), patients were centrally randomised in Synvisc (S) or in usual treatment (UT) groups. S-patients were treated by 3 intraarticular injections of Hylan GF 20 one week apart and encouraged to stop or spare any other OA treatments. If needed S-patients could be treated by Synvisc in both knees. Primary outcome was difference in specific knee-OA cost (visits, exams, hospitalisations, treatments and adverse event treatment/prevention related to OA treatments) divided by difference in AUC mean change of Lequesne index between groups. Data were collected at baseline, day 28, months 3, 6 and 9. <h3>Results</h3> Out of 518 patients randomised, 506 (253 per group) were treated and evaluable. Both groups were comparable at baseline. Forty-five S-patients (18%) were treated in both knees. Cost per patient was analysed over 9 months in social security perspective (year 1998 value). All direct and indirect costs were decreased in S-group compared to UT-group (medications ? 40%, non-drug treatments ? 19%, hospitalisation ? 5%, exams ?2%, seak-leave ? 15%) with the only exception of physician visits cost (+ 33%) due to Synvisc injection procedure. Specific OA total costs (including Synvisc) were 829.12 Euros in S-group and 821.34 Euros in UT-group. Synvisc cost in social security perspective (year 2000 value) is 99.09 Euros per treatment. AUC mean change in Lequesne Index was 7.9 points in S-group vs 9.9 in UT-group (p &lt; 0.0001). All together the cost/efficacy ratio (including Synvisc cost) was 7.78 Euros for a 2-point improvement of Lequesne index (difference clinically significant) between groups. <h3>Conclusion</h3> Viscosupplementation by Synvisc improves algofunctional status of patients and has no significant impact on specific knee OA cost. <h3>Acknowledgement</h3> Synvisc Experts Group: Prs. Bardin T., Dougados M., Kahan A. (Paris), Mazières B (Toulouse), Trèves R. (Limoges), Vignon E. (Lyon), Drs Auvinet B. (Laval), Naim C. (Marseille), Rossignol O. (Fontenay).